Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: the impact GLP-1 CKD study
Side effects are generally mild and well-tolerated
Tirzepatide is sold as Mounjaro for T2D and Zepbound for obesity in the US, and the two brands grew 110% and 123% to $7.41 billion and $4.26 billion, respectively, in the last quarter of 2025, year-on-year
doi: 10.1359/JBMR.041122 122 OtsukaSAoyamaTFuruMItoKJinYNasuAet al
A single unexpected result is rarely acted on alone
US$ 27.58
US$ 28.94
US$ 29.53
)
US$ 21.83
US$ 26.64
US$ 19.99
